Board of Aurobindo Pharma approves acquisition of 80% stake in Tergene Biotech

The Board of Aurobindo Pharma at its meeting held on 06 February 2025 has approved to purchase back the entire 80% equity ownership of Tergene Biotech, a step-down subsidiary of the Company, held by Auro Vaccines, a wholly owned stepdown subsidiary of the Company. On completion of the transaction, Tergene Biotech will become a direct subsidiary of the Company.